Venous thromboembolism (VTE) is a significant health problem in the general population
but especially in cancer patients. In this review, we discuss the epidemiology and burden of …

Venous thromboembolism (VTE) is the second leading cause of death in patients with
cancer. These patients are at an increased risk of developing VTE and are more likely to …

Venous thromboembolism (VTE) is the second leading cause of death in patients with
cancer. These patients are at a high risk of VTE recurrence and bleeding during …

Venous thromboembolism (VTE) is a preventable cause of postoperative morbidity and
mortality; however, audits suggest that the use of thromboprophylaxis is underused. In this …

Context Pharmacological thromboprophylaxis involves balancing a lower risk of venous
thromboembolism (VTE) against a higher risk of bleeding, a trade-off that critically depends …

Objective Postoperative venous thromboembolism (VTE) creates an 8-fold increase in
mortality after lung resection. About one third of postoperative VTEs occur after discharge …

Venous thromboembolism (VTE) is a preventable disease, thus, in a number of clinical
situations primary thromboprophylaxis has been proposed. Although we now know that …

Venous thromboembolism (VTE) is a clinical disease that includes deep vein thrombosis
and pulmonary embolism. Amongst its underlying risk factors, cancer is of great importance …

Pulmonary hypertension (PH), defined by a mean pulmonary artery pressure of> 25mm Hg
at rest, is strongly associated with morbidity and mortality in the perioperative period. The …

Background This study primarily evaluates the risk of recurrent venous thromboembolism
(VTE) and major bleeding (MB) among patients with VTE and active cancer prescribed …